PR Newswire, Aug. 7, 2013 - Partner Rob Funsten represented Lupin Pharmaceuticals Inc. in a recent strategic licensing agreement with U.S. pharmaceutical company Romark Laboratories, L.C. The agreement grants Lupin exclusive rights to promote, distribute and market Alinia (nitazoxanide) for oral suspension in the U.S. Alinia (nitazoxanide) is the first thiazolide approved by the FDA for the treatment of diarrhea caused by Cryptosporidium and Giardia and is the only FDA-approved treatment for Cryptosporidium. Funsten was assisted by partners Hill Wellford and Brandon Bigelow.